Beyond Gravity: The Impact of Microgravity and Spaceflight on Human Pharmacokinetics and Drug Response

Spaceflight obtrude dramatic physiological commute on the human body that can modify each stage of drug pharmacokinetics (absorption, distribution, metabolism, excretion) and pharmacodynamics. Decades of space medication investigate recommend that liquid shifts, organ work modifications, and stressors in microgravity influence medicate behaviour, but precise information are rare. This review looks at recent (2023–2025) human and in vitro studies on pharmacokinetics in space environments. Key discoveries incorporate altered drug absorption (e.g. inhibited intestinal P-glycoprotein increasing oral bioavailability), decreased plasma volume changing distribution volumes, and tweaked liver enzyme articulation influencing medication metabolism. We moreover talk about drug stability issues: shelf-life analyses uncover that most ISS drugs lapse within 2–3 years (Fig. 2), posturing risks for long missions. Exploratory models (parabolic flights, cell clinostats, rodent hindlimb suspension) have started to measure these impacts. For illustration, parabolic-flight thinks about with caffeine found no noteworthy change in CYP1A2-intervened metabolism over seconds of weightlessness, whereas simulated microgravity depressed intestinal medicate efflux, particularly increasing acetaminophen uptake in rodents. In vitro cancer models appear modified medicate sensitivity beneath microgravity, implying potential changes in pharmacodynamics. The lack of inflight PK/PD trials is evident; leading reviews point-up the critical require for dedicated space pharmacology research. In summary, current confirmation shows that microgravity can essentially alter drug activity. Future missions need moved forward pharmacokinetic information (including omics-guided personalized approaches) and validated countermeasures (e.g. tailored dosing, protective preparation & formulations).